Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Poseida Therapeutics, Inc. (PSTX : NSDQ)
 
 • Company Description   
Poseida Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing therapeutics for high unmet medical needs. The company is developing a pipeline of solutions for the treatment of hematological malignancies and solid tumors, as well as vivo programs for liver-directed gene therapies for rare diseases. In addition, it offers CAR-T therapies for the treatment for cancer. Poseida Therapeutics Inc. is based in San Diego, California.

Number of Employees: 263

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.10 Daily Weekly Monthly
20 Day Moving Average: 269,256 shares
Shares Outstanding: 62.71 (millions)
Market Capitalization: $131.68 (millions)
Beta: 1.00
52 Week High: $11.10
52 Week Low: $1.83
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -31.60% -22.96%
12 Week -41.01% -35.15%
Year To Date -69.16% -63.76%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
9390 Towne Centre Drive Suite 200
-
SAN DIEGO,CA 92121
USA
ph: 858-779-3100
fax: -
None http://www.poseida.com
 
 • General Corporate Information   
Officers
Mark J. Gergen - Chief Executive Officer and Director
Eric Ostertag - Executive Chairman and Director
Johanna M. Mylet - Chief Financial Officer
Cynthia Collins - Director
Luke Corning - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 73730P108
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/11/22
Share - Related Items
Shares Outstanding: 62.71
Most Recent Split Date: (:1)
Beta: 1.00
Market Capitalization: $131.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.69 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-3.19 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 1.75% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/11/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.27
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -50.00%
vs. Previous Quarter: -4,750.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -95.41%
ROE
03/31/22 - -97.02
12/31/21 - -69.39
09/30/21 - -78.72
ROA
03/31/22 - -53.67
12/31/21 - -42.96
09/30/21 - -51.38
Current Ratio
03/31/22 - 4.34
12/31/21 - 4.94
09/30/21 - 6.44
Quick Ratio
03/31/22 - 4.34
12/31/21 - 4.94
09/30/21 - 6.44
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -442.92
12/31/21 - -400.07
09/30/21 - -
Book Value
03/31/22 - 1.65
12/31/21 - 2.50
09/30/21 - 2.41
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.56
12/31/21 - 0.19
09/30/21 - 0.20
Debt-to-Capital
03/31/22 - 35.85
12/31/21 - 15.82
09/30/21 - 16.33
 

Powered by Zacks Investment Research ©